Aaron T. Gerds, MD, MS, discusses the 48-week results of the MOMENTUM trial of momelotinib, a JAK1/JAK2 inhibitor that is being investigated specifically for the treatment of anemic patients with myelofibrosis.
Aaron T. Gerds, MD, MS
Aaron T. Gerds, MD, MS, is the editor-in-chief of ASH Clinical News, serves as the deputy director for clinical research at Cleveland Clinic Taussig Cancer Institute, and is an associate professor at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, both in Cleveland, Ohio.
Articles by Aaron T. Gerds, MD, MS
Aaron Gerds, MD, MS, offers closing remarks on the outlook for the treatment of myelofibrosis, and shares advice for community oncologists.
A thorough review of promising therapies currently under investigation for the treatment of myelofibrosis.
An expert oncologist overviews quality-of-life data and considerations in treatment sequencing in myelofibrosis.
Aaron Gerds, MD, MS, discusses the MOMENTUM study and the potential role of momelotinib in the myelofibrosis treatment landscape.
A comprehensive overview of ruxolitinib, fedratinib, and pacritinib, the approved therapies for the treatment of myelofibrosis.
An expert on hematologic malignancies discusses the prognostic factors and molecular pathways involved in myelofibrosis.
Aaron Gerds, MD, MS, explains the types, presentations, and classic symptoms of myelofibrosis.
Aaron T. Gerds, MD, MS, discusses the clinical trial development of momelotinib, a JAK1/JAK2 inhibitor that is being investigated for the treatment of patients with myelofibrosis.
Aaron Gerds, MD discusses the results of a phase II BELIEVE study of luspatercept as treatment of patients with myelofibrosis-associated anemia.